ID   NCI-H2452
AC   CVCL_1553
SY   H2452; H-2452; NCIH2452
DR   CLO; CLO_0008077
DR   EFO; EFO_0006680
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5946
DR   BioSample; SAMN03471009
DR   BioSample; SAMN10988138
DR   BioSamples; SAMEA100910
DR   CCLE; NCIH2452_PLEURA
DR   CCRID; 3131C0001000700213
DR   CCRID; 3131C0001001200017
DR   Cell_Model_Passport; SIDM00722
DR   ChEMBL-Cells; CHEMBL3308580
DR   ChEMBL-Targets; CHEMBL1075540
DR   Cosmic; 886392
DR   Cosmic; 908462
DR   Cosmic; 1032373
DR   Cosmic; 1481546
DR   Cosmic; 1522763
DR   Cosmic; 1541212
DR   Cosmic; 1571798
DR   Cosmic; 1749557
DR   Cosmic; 1963328
DR   Cosmic; 1995571
DR   Cosmic; 2474096
DR   Cosmic-CLP; 908462
DR   DepMap; ACH-000092
DR   GDSC; 908462
DR   GEO; GSM726266
DR   GEO; GSM827515
DR   GEO; GSM850285
DR   GEO; GSM887424
DR   GEO; GSM888503
DR   GEO; GSM1670234
DR   LiGeA; CCLE_468
DR   LINCS_LDP; LCL-1230
DR   PharmacoDB; NCIH2452_1092_2019
DR   Wikidata; Q54907975
RX   PubMed=7695406;
RX   PubMed=8806092;
RX   PubMed=11030152;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21245096;
RX   PubMed=21642991;
RX   PubMed=22460905;
RX   PubMed=24926545;
RX   PubMed=25485619;
RX   PubMed=25902174;
RX   PubMed=25984343;
RX   PubMed=26011428;
RX   PubMed=27397505;
RX   PubMed=28553954;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
WW   http://www.cellresource.cn/fdetail.aspx?id=1598
WW   http://www.cellresource.cn/fdetail.aspx?id=1717
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Doubling time: 48 hours (PubMed=25984343).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for BAP1 p.Ala95Asp (c.284C>A) (PubMed=21642991; PubMed=26011428).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.27%; Native American=0%; East Asian, North=1.66%; East Asian, South=0%; South Asian=0%; European, North=63.32%; European, South=34.76% (PubMed=30894373).
ST   Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 11,13
ST   D18S51: 15
ST   D21S11: 28,32.2
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   D8S1179: 10
ST   FGA: 23
ST   Penta D: 9
ST   Penta E: 12,15
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C45665; Pleural biphasic mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 29
//
RX   PubMed=7695406; DOI=10.1016/0003-4975(95)00045-M;
RA   Pass H.I., Stevens E.J., Oie H.K., Tsokos M.G., Abati A.D., Fetsch P.A.,
RA   Mew D.J.Y., Pogrebniak H.W., Matthews W.J.;
RT   "Characteristics of nine newly derived mesothelioma cell lines.";
RL   Ann. Thorac. Surg. 59:835-844(1995).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164;
RA   Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T.,
RA   Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H.,
RA   Sekido Y.;
RT   "LATS2 is a tumor suppressor gene of malignant mesothelioma.";
RL   Cancer Res. 71:873-883(2011).
//
RX   PubMed=21642991; DOI=10.1038/ng.855;
RA   Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L.,
RA   Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R.,
RA   Powell S., Zhou Q., Shen R., Olshen A.B., Rusch V., Ladanyi M.;
RT   "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic
RT   mutations and 3p21.1 losses in malignant pleural mesothelioma.";
RL   Nat. Genet. 43:668-672(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24926545; DOI=10.1097/JTO.0000000000000202;
RA   Riquelme E., Suraokar M.B., Rodriguez J., Mino B., Lin H.Y.,
RA   Rice D.C., Tsao A., Wistuba I.I.;
RT   "Frequent coamplification and cooperation between C-MYC and PVT1
RT   oncogenes promote malignant pleural mesothelioma.";
RL   J. Thorac. Oncol. 9:998-1007(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26011428; DOI=10.1111/cas.12698;
RA   Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y.,
RA   Yokoi K., Sekido Y.;
RT   "Functional differences between wild-type and mutant-type
RT   BRCA1-associated protein 1 tumor suppressor against malignant
RT   mesothelioma cells.";
RL   Cancer Sci. 106:990-999(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28553954; DOI=10.1038/onc.2017.147;
RA   Kato T., Sato T., Yokoi K., Sekido Y.;
RT   "E-cadherin expression is correlated with focal adhesion kinase
RT   inhibitor resistance in merlin-negative malignant mesothelioma
RT   cells.";
RL   Oncogene 36:5522-5531(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574-3574(2019).
//